# Centro Brasileiro de Estudos em Dermatologia

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/centro-brasileiro-de-estudos-em-dermatologia/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 89 |
| Citations | 5,894 |
| City | Porto Alegre |
| Country | BR |
| Description | Centro Brasileiro de Estudos em Dermatologia is a research organisation in Porto Alegre, BR. OpenAlex records 357 works and 5,894 citations for it. 136 researchers list it as their most recent affiliation. |
| Homepage | http://www.cbed.org.br/site/index.html |
| OpenAlex ID | https://openalex.org/I4210089557 |
| Researchers | 136 |
| ROR ID | https://ror.org/008egzn26 |
| Type | other |
| Works | 357 |

## University papers

Showing 12 of 14.

- [Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-after-adjuvant-chemotherapy-in-her2-positive-breast-cancer/)
- [Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-in-patients-with-previously-treated-non-small-cell/)
- [Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renal-cell-carcinoma/)
- [Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-previously-untreated-pd-l1-expressing/)
- [Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-alone-or-with-chemotherapy-versus-cetuximab-with-chemotherapy-for/)
- [3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)](https://scholariq.org/papers/3rd-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-3/)
- [Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-cabozantinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/)
- [Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-pd-l1-selected-patients-with-nsclc/)
- [ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer](https://scholariq.org/papers/esmo-clinical-practice-guideline-for-the-diagnosis-staging-and-treatment-of/)
- [Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer](https://scholariq.org/papers/primary-results-from-impassion131-a-double-blind-placebo-controlled-randomised/)
- [Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/neratinib-after-trastuzumab-based-adjuvant-therapy-in-her2-positive-breast/)
- [Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma](https://scholariq.org/papers/phase-ii-randomized-trial-comparing-sequential-first-line-everolimus-and-second/)

## University top topics

Showing 8 of 25.

- [Dermatologic Treatments and Research](https://scholariq.org/topics/dermatologic-treatments-and-research/)
- [Facial Rejuvenation and Surgery Techniques](https://scholariq.org/topics/facial-rejuvenation-and-surgery-techniques/)
- [Public Health in Brazil](https://scholariq.org/topics/public-health-in-brazil/)
- [Avian ecology and behavior](https://scholariq.org/topics/avian-ecology-and-behavior/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Nail Diseases and Treatments](https://scholariq.org/topics/nail-diseases-and-treatments/)
- [Health, Nursing, Elderly Care](https://scholariq.org/topics/health-nursing-elderly-care/)
- [Fungal Infections and Studies](https://scholariq.org/topics/fungal-infections-and-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.